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Summary Various types of anti-neoplastic agents induce apoptosis in vitro, but less is known of the role of this mode of cell death in tumours
treated in vivo. We examined the induction of apoptosis by oral anti-neoplastic agents, tegafur and uracil (UFT, a combined preparation of
1 mol tegafur and 4 mol uracil), and the relationship of effects on tumour growth. Seven different human gastrointestinal tumour xenografts
were transplanted into nude mice, including two colon adenocarcinomas (KM20C and Col-1), three gastric carcinomas (SC-6, St-40 and 4-
1ST) and two pancreatic carcinomas (PAN-4 and PAN-12), followed by oral administration of UFT (24 mg kg-' day-') for 9 days. The
percentage of apoptotic cells in each tumour was scored in histological sections, chronologically, using a molecular biological-histochemical
system and growth inhibition was examined in each tumour.
A significant growth inhibition by UFT was observed for all tumours, except PAN-12. In KM20C and SC-6, growth inhibition rates were
61.7% and 60.6% respectively. Quantitative assay for apoptosis showed a remarkable induction of apoptosis in KM20C (4.2%) and SC-6
(3.5%), which were relatively sensitive to UFT. In addition, KM20C and SC-6 showed a higher incidence of spontaneous apoptosis. In five
other tumours, which responded to a lesser extent than KM20C and SC-6, UFT altered little the changes in apoptosis (less than 2%) and
spontaneous apoptosis was relatively low.
Thus, turnours with a higher apoptosis induced by UFT had a higher response to UFT. Apoptosis observed in tumours might serve as a
predictor of a preferable response to UFT.
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UFT. a compound containing 1-(2-tetrahydrofuiryl)-5-fluorouracil
(tegafur) and uracil at a molar ratio of 1:4. is based on the
biochemical modulation of tegafur by uracil (Fujii et al. 1978.
1979). Tegafur is metabolized to 5-fluorouracil (5-FU) by P-450.
mainly in liver microsomes (Blokhina et al. 1972. Toide et al.
1977). Uracil suppresses the degradation of 5-FU but does not
inhibit phosphorylation for activation of 5-FU. so that UFT
produces a higher 5-FU level in the blood and enhances anti-
tumour activity (Schumacher et al. 1969: Ikenaka et al. 1979). In
animal studies. higher 5-FU levels in the blood and tumour tissues
were noted after the administration ofUFT than tegafur and 5-FU
(Fujii et al. 1978. 1979). UFT is more anti-neoplastic than 5-FU.
tegafur and l-hexylcarbamoyl-5-fluorouracil (HCFU) against
gastric cancer tissues. as determined using an in vivo chemosensi-
tivity test (Maehara et al. 1988). UFT has been widely prescribed
for patients in Japan with gastrointestinal cancers (Ota et al. 1988:
Maehara et al. 1992. 1994). Several institutions in the USA haxe
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carried out clinical studies on UFT (Pazdur et al. 1994: Muggia et
al. 1996). Despite extensive studies. the clinical outcome of UFf
against gastrointestinal cancers is not always satisfactory.
Apoptosis. one mode of cell death. plays important roles in the
regulation oftissue development. It appears to have a complemen-
tary. but opposite. role to mitosis in regulating animal cell popula-
tions (Kerr et al. 1972). Apoptosis also occurs in tumours and
functions in determining tumour growth (Kerr and Searle. 1972;
Wyllie. 1992). Apoptosis is induced in cancer cells in response
to radiation (Lichter and Lawrence. 1995). drugs (Dive and
Hickman. 1991: Fisher. 1994) and hyperthermia (Dyson et al.
1986: Barry et al. 1990). Should there be a correlation between
anti-cancer effects and apoptosis induced by therapeutic agents in
vivo. apoptosis could be a target of or a predictor of anti-cancer
therapies. In studies undertaken to show the importance of apo-
ptosis in anti-cancer therapies. cancer cells in vitro were used and
the correlation between apoptosis and cytotoxicity was evident
(Fisher et al. 1993: Lowe et al. 1993: Fisher. 1994). Few such
attempts have been made in vivo. To quantitate apoptosis induced
by oral anti-neoplastic agents in vivo would be one approach to
better understand related events.
We quantitated the proportion of apoptotic cells induced by an
oral anti-neoplastic agent. UFT. For this. we used seven human
gastrointestinal tumour xenografts in nude mice and we evaluated
the relationship between apoptosis and drug sensitivity.
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MATERIALS AND METHODS
Animals
Balb/c-nu/nu mice. 6-10 weeks old and purchased from Clea
Japan (Tokyo. Japan). were housed at controlled temperature.
humidity and a 12:12 h light-dark cycle. under aseptic conditions.
Human tumour xenografts
The colon cancer cell line KM20C Bras kindly provided by
Professor Kiyoshi Morikawa. Iwamizawa Worker's Compensation
Hospital. Iwamizawa. Japan. Colon cancer cell line Col-1. three
aastric cancer cell lines. SC-6. St-40 and 4-1ST. and two pancre-
atic cancer cell lines. PAN-4 and PAN-12. were obtained from the
Central Institute for Experimental Animals (Kawasaki. Japan).
Each tumour was xenotransplantated into nude mice. The growing
tumour was excised and cut into 2-3 mm pieces. The tumour frag-
ments were implanted subcutanously into the dorsum of nude
mice. After transplantation. tumour size was measured using
calipers and the tumour volume was estimated according to the
following formulae: tumour volume (mm") =LxW2/2. where L is
the length and W is the width.
Antineoplastic agent
The anti-neoplastic agent UFT. prepared to be given orally. is a
combined preparation of 1 mol tegafur and 4 mol uracil developed
by Taiho Pharmaceutical Co. (Tokyo. Japan). After dissolution in
distilled water. UFT was administered by gavage in a dose of
24 mg kg-' day-'.
Treatment protocol
The treatment was initiated on dav 0 when tumour volume reached
100-300 mmr in each group (usually 2-3 weeks after inoculation).
In the treatment group. UFT was orally administered in a dose of
24 mig kg--' day-' for 9 days. In the control mice. normal saline was
administered using the same schedule and volume. Mice were
randomized into two groups. the control group and the treatment
group. each group consisting of 37 mice. Seven mice in each
group were set apart for the evaluation of tumour growth. The
other tumour-bearing mice were killed on days 4. 7. 10. 14. 21 and
28 and examined histologically. Five mice were included at each
time point.
Tumour growth inhibition rate was evaluated on day 14. based
on the formulae (T--T1)/Tc. where T is the tumour volume of the
control group and Tt that ofthe treated group.
Table 1 Rate of tumour growth inhibition in seven human gastrointestinal
tumours following oral ingestion of UFT (day 14)
Tumour Growth inhibition rate (%)
KM-20C 61.7
SC-6 60.6
PAN-4 48.0
St-40 39.4
Col-1 36.6
4-1ST 34.8
PAN-12 5.1
3'-hydroxy ends of fragmented DNA. Then anti-digoxigenin anti-
body conjugated with peroxidase was applied to the sections to
detect the labelled nucleotides. The antibody was localized with
3.3'-diaminobenzidine tetrahydrochlonrde and 0.065% sodium
azide was used to blockendogenous peroxidase. The sections were
counterstained with Giflls haematoxylin.
Apoptotic cells in the sections were counted by microscopic
examination at 400x magnification and the percentage of apo-
ptotic cells was calculated as the numberper 100 nuclei in the non-
necrotic areas. Apoptosis index (Al) was determined as the mean
of the percentages of apoptotic cells from ten independent.
randomly selected fields.
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Quantification of apoptosis
Apoptosic cells in the tumour were counted using a molecular
biological-histochemical system (ApopTag Peroxidase Kit.
Oncor. Gaithersburg. MD. USA). which is based on the terminal
deoxynucleotidyl transferase (TdT)-mediated dUTP-biotin nick
end labelling (Tunel) method (Gavrieli et al. 1992). After deparaf-
finizing the formalin-fixed and paraffin-embedded tissue sections.
proteins in specimens were digested using proteinase K. The
endogenous peroxidase activity was quenched with 2% hydrogen
peroxide in phosphate-buffered saline (PBS). then the sections
were incubated with a working strength of TdT enzyme at 370C
for I h to add the diaoxigenin-labelled deoxyuridines to the
I- P<0.01
, P<0.05
Days after start of treatment
Figure 1 Tumour growth curves of the KM20C, SC-6, PAN-4, St-40, Cdl-1,
4-1ST and PAN-12 tumours up to day 14. Open circles, control groups and
dosed circles, treated groups. Bars in the figure show the term of drug
administration. AM mice of control groups eventually developed progressrvely
growing tumours. Significant inhibition was observed in all tumours but in
PAN12. (UP< 0.01, *P< 0.05)
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Figure 2 Photomicrographs show features ofapoptosas in the control group (A and C) and the treated group (B and D) at 260x magnification (A and B,
haernatoxylin and eosin; C and D, Tunel method) in KM20C turnour. The arrows are directed to features of apoptosis of a single round mass with condensed,
homogneou, strongly eosinophific cytoplasm with some round dumps of homogeneous, strongly basophilic materials representing chromatin condensation.
Arrowheads are directed to another feature of apoptosis, that is fragments of condensed chromatin material not surrounding thecytoplasm. The numbers of
apoptotic cells in the treated group (B and D) were higher than the control group (A and C)
Immunohistochemistry
The sections were immunostained with a monoclonal antibody
against Ki-67 (MIB1: Immunotech. Marseille. France) or against
p53 (PAbl8O1: Oncogene Science. Union Dale. NY USA). The
deparaffinized sections were autoclaved at 1210C in 0.1 m PBS
(pH 7.4) to allow the fixed embedded tissue antigen to react with the
monoclonal antibody. These sections were then covered with normal
rabbit serum to reduce non-specific staining and then incubated with
a 1:100 dilution of the primary antibody. The sections were incu-
bated with a 1:600 dilution of biotinylated rabbit anti-mouse IgG
(Dako Japan. Kyoto. Japan) and then covered with a 1:1000 dilution
of streptavidin-peroxidase complex (Dako Japan.). The activity of
the peroxidase was detected with diaminobenzidine.
Statistical method
The data were expressed as the means ± standard deviation. The
statistical significance was confirmed using Mann-Whitney's
U-test and the difference was considered significant when the
P-value was less than 0.05.
RESULTS
Antitumour effect of UFT in gastrointestinal tumour
xenografts
We investigated tumour growth of the seven independent tumour
xenografts when UFT (24 mg kg-' day-') was orally administered
to the mice for 9 days. The dose was determined by basing it on the
finding that the anti-tumour effect ofUFT correlated linearly with
its dose in a range below 24 mg kg-' day-' (data not shown). When
more than 24 mg kg-' day-' of UFT was administered to the mice,
they lost much weight and some died during the course ofexperi-
ment. Figure 1 shows growth curves of the tumours during the
14 days. All mice in the control group developed tumours
progressively. Significant inhibition of growth by UFT treatment
was observed for all tumours except PAN12. Table 1 shows the
rates of inhibition of tumour growth on day 14 in all the tumours.
including KM20C. The rates of inhibition of tumour growth in
KM20C and SC-6 exceeded 50%. that is the ED-, of UFT at the
dose given.
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Figure 3 Kinetics of apoptosis development in the KM20C tumour after oral
administraton of 4 mg kg-' day-' of UFT. Mice were killed at different times
and apoptosis was scored in histologic sections of the tumours. Open
circles, control group and closed circles, treated group. The percentage of
apoptotc cells (apoptosis indexA]) in the control group showed littie change
from dayO to day 28. In contast, in the treated group, the Al increased to
4.2% on day 14 and was significantly higher than in the control group from
day 4 to day 21 (PcO.01)
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Figure 4 Induction of apoptosis for seven human turnour xenografts on day
14 after treatment with UFT, as based on the sensitivity to UFT treatment
(Table 1). Apoptosis wassgnificantly induced by UFT treatment in KM20C
and SC-6. The otr five tumours showed no significant difference in
apoptosis induction by UFT
Induction of apoptosis by UFT in KM20C colon tumour
xenografts
We then investigated the kinetics of apoptosis in a KM20C colon
tumour xenograft- a lesion most sensitive to UFT (Table 1).
Photomicrographs showing the features ofapoptosis in the KM2OC
tumours are presented in Figure 2. We confirmed that the cells
which were positively stained by the Tunel method had morpholog-
ical features of histologically identified apoptotic cells by staining
consecutive sections with haematoxylin and eosin (HE). The
features of apoptotic cells in our present study are summarized as
follows: (1) a single round mass with condensed. homogeneous.
strongly eosinophilic cytoplasm with some round clumps of
homogeneous. strongly basophilic materials representing chromatin
Ri2=0.853
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Figure 5 Correlation between apoptosis and tumour growth inhibition. The
UFT-induced apoptosis positively correlated (FR=0.625) wit the response to
UFT (A). Frequency of the spontaneous apoptosis more strornly correlated
with sensivity to the UFT (FR=0.853) (B)
condensation (arrows) or (2) fragments of condensed chromatin
material without surroundingcytoplasm (arrowheads). The numbers
ofapoptotic cells in the treated group (B and D) were higher than in
the control group (A and C).
Figure 3 shows the time course ofthe extent ofapoptosis induced
by UFT in KM20C. The percentage of apoptotic cells (apoptosis
index. Al) in the control group did not change significantly. In
contrast. in the treated group. Al gradually increased up to the peak
level of about 4% on days 14 and 21. and control levels were
reached on day 28. The level was significantly higher than in the
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control group fromday4today 21 (P <0.01). The elevated level of
apoptosis continued even after cessation ofdrug administration.
Thus, in the KM20C tumour, UFT produced a marked tumour
growth inhibition and induced an apoptosis which was most
prominent 14days after the start of treatment.
Effects of UFT on cell proliferation
To assess the anti-tumour effect of UFT on cell growth inhibition.
we investigated the proliferation activity in the xenografts using
anti-Ki-67 antibody (MIB-1) immunohistochemistry on day 14.
There was no significant difference between the treated group and
the untreated group in any tumour(data not shown).
Relationship between the induction ofapoptosis and
anti-tumour effect
Figure 4 shows the Als on day 14 for each tumour, based on the
sensitivity to UFf treatment (Table 1). Asignificantlyhigher level
ofapoptosis was induced by UFT treatment in KM20C and SC-6.
In the other five tumours. which showed no or a smaller response
to UFT compared with KM20C and SC-6 (Figure 1 and Table 1).
there was no significant difference in apoptosis inductionby UFT.
In the KM20C and SC-6 tumours. which were more sensitive to
UFT, a relatively higher incidence of spontaneous apoptosis was
observed in the controls. Figure 5 shows that the UlFT-induced
apoptosis positively correlated (R2=0.625) with the rate ofgrowth
inhibition (Figure 5A). The frequency of spontaneous apoptosis
more strongly correlated with the rate of inhibition (R2=0.853)
(Figure SB).
To examine the induction of apoptosis in normal tissue, we
investigated apoptosis in the normal ileum and the spleen ofnude
mice. The level was too low to show any difference in induction
rate between controls and treated groups.
p53 immunohistochemistry in seven tumourxenografts
Nuclear p53 staining revealed that SC-6 and Col-1 had the wild-
type p53. while KM20C. PAN4 St-40 461ST and PAN-12 had
the mutant-type p53. PCR readily revealed the amplified product
ofp53 alleles in SC-6 and Col-1,indicating that neither allele had
any biallelic loss. Judging from the results of immunohistochem-
istry using anti-p53 antibody. KM20C was the p53 mutant and
SC-6 was the wild type, althoughthey proved to be the most UFT-
sensitive tumours.
DISCUSSION
Although numerous studies have been done onapoptosis ofcancer
cells induced by anti-neoplastic agents in vitro (Barry et al. 1990:
Fisher et al. 1993: Lowe et al. 1993),in vivo-related documenta-
tions are few. Some anti-neoplastic agents.including 5-FU. have
been reported to induce apoptosis in tumour xenografts (Meyn et
al, 1994. 1995a, 1995b). When we examined the apoptosis
inducedby UFT. a combined oralpreparation oftegafur and uracil.
and its anti-tumour effects in human tumour xenografts in mice.
we found that UFTinducesapoptosis in human tumourxenografts.
as do other anti-neoplastic agents. Although the seven lineages of
tumour xenografts we examined here responded to UFT with
different sensitivities.there was apositive correlation between the
extent of apoptotic induction and the anti-tumour effect of UFT.
Pathways leading to apoptosis are highly complicated. and
apoptosis is dependent on cell type and type of stimuli. Although
determinants of induction of apoptosis might be different among
the tumour xenografts used here. tumours exhibiting a high inci-
dence of apoptosis responded well to oral administration of UFT.
This finding is important because the correlation between apop-
tosis and growth inhibition has diagnostic significance for cancer
patients treated with anti-neoplastic agents. By histologically
examining apoptosis during chemotherapy. the effect of anti-
neoplastic agents can be monitored. Spontaneous apoptosis
observed in untreated tumour xenografts also correlated with the
anti-tumour effect of the UFT, as well as the apoptosis induced in
tumour xenografts treated with the agent. The spontaneous apop-
tosis observed in this study may be that induced by various stimuli
such as hypoxia or low pH. Spontaneous apoptosis may well
reflect the potential to induce apoptosis in response to anti-
neoplastic agents. Pre-existing apoptosis before treatment is much
more suitable for histological examination than that induced
during the course of treatment. We propose that apoptosis
observed in tumours is an important indicator to assess the growth
inhibitory effect ofanti-neoplastic agents.
In the four cell lines used here. tumour growth was remarkably
retarded despite the finding that apoptosis was not increased
significantly. Therefore, we also investigated activity of cell
growth in the tumour xenografts by immunohistochemistry, using
an anti-Ki67 antibody. Differences between the group with an
increased incidence of apoptosis and that showing no change in
apoptosis were nil. Inhibition ofcell proliferation may be predom-
inant in tumours with a decreasing volume. without the induction
of apoptosis. In almost all the xenografts we used. necrosis was
observed in the core ofthe tumourxenografts on day 14. Although
we macroscopically compared the necrotic areas in UFf-sensitive
tumours with those in the other four tumours. there was no differ-
ence in appearance (data not shown). The role of necrosis in
growth inhibition induced by anti-neoplastic agents is unclear. as
there is no available pertinent method to evaluate necrosis quanti-
tatively in vivo.
In studies done by Meyn et al (1994. 1995b). apoptosis in the
murine tumour peaked within several hours or at least one day
after administration of anti-neoplastic agents or irradiation.
However in our study. 14 days was required to reach the peak.
Possible explanations for the slow induction of apoptosis are as
follows: UFT is a combined preparation oftegafur and uracil and
tegafur is converted to 5-FU by metabolic processing in the liver.
Uptake into the systemic circulation of a drug administered orally
is slower than that of a drug injected intravenously, in which the
blood concentration ofthe drug peaks within a few hours (Meyn et
al. 1994. 1995a. 1995b). Thus. in our experiment. the tumours
were consistently exposed to a lower concentration of the anti-
cancer drug UFT. It was reported that a bolus injection of 5-FU
induced a greater extent ofapoptosis in the thymus and the ileum.
while continuous infusion of5-FU. the pharmacokinetics ofwhich
is similar to that of our experiment induced a lower level of apo-
ptosis in the thymus and minimal apoptosis in the ileum
(Sakaguchi et al,1994). Investigating Al in the ileum of the mice
used here, we have found no difference between the treatedgroups
and the controls. It seems that, in our experiments. UFTinduced
apoptosis with a slower kinetics. mainly in tumour tissues. and
minimal apoptosis in normal tissues.
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The genetic status of p53 did not correlate with the anti-tumour
effect of lFT and the apoptosis induced by the agent. Although
increased resistance to radiation or DNA-damaring agents was
noted in p53-deficient cells or cells harbouring a mutated p53
gene. p53-independent pathways have also been reported during
apoptosis (Kondo et al. 1996: Strobel et al. 1996: Vasey et al.
1996). As shown in KM2OC. a p53-mutant cell line. UFf may
possibly activ-ate p53-independent pathways and consequently
induce growth retardation and apoptosis. Induction ofapoptosis in
p53-mutant cells by UFF is a positive finding which will aid in
treating patients with p53 mutant tumours.
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